Innate Pharma S.A. ADS (IPHA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 37/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.12% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
- Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?
- Innate Pharma Reports First Half 2026 Business Update and Financial Results
- Sobi and Innate announce partnership is now effective following completion of closing conditions
- Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
- Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ...
- Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Innate Pharma S.A. ADS.
Full IPHA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.